Click to listen highlighted text! Powered By GSpeech

Home » Posts tagged 'competition law'

Tag Archives: competition law

Are integrated care packages like M&Ms? Expect a competition law armageddon.



IMAGES

Somewhere along the path of the subconscious of this current Government they realised competition law, as the trojan horse for implementing the private market of the NHS, would be the ‘nuclear option’ gone too far.

After the original set of section 75 NHS regulations had been humiliatingly scrapped, Norman Lamb and other LibDem members in the Upper and Lower House had to ferret around for another way to sell this discredited policy. They found ‘integration’.

The idea of co-ordinated care bundles, delivering outcomes across a range of different domains, seems like an attractive one. For the privateers, their uncanny similarity to the Kaiser Permanente Integrated Care Plan is of course enticing.

Thrust on this that private providers can cobble together au “uber contract”, subcontracting bits of it to various bods, through the ‘prime contractor model’ – and job done.

However, this way of integrating services is a ‘red rag’ to the bull of the competition authorities both here and across the pond.

You have to have been living on the Planet Mars to escape the screw-ups of the regulation of the energy market in the UK.

In 2008, the Telegraph reported the following:

Regulator tells Treasury it has found no evidence that energy companies colluded to increase bills…
Energy watchdog Ofgem has dismissed suggestions that the UK’s six largest energy companies colluded to increase gas and electricity bills. The regulator has also demanded that those alleging price-fixing should produce the evidence.
Alistair Darling, the Chancellor, summoned Ofgem chairman Sir John Mogg and chief executive Alistair Buchanan after Npower, owned by the German giant RWE, last week increased gas prices by 17pc and electricity prices by 13pc.
Mr Buchanan said yesterday: “We have no evidence of anti-competitive behaviour. We see companies gaining and losing significant market share, record switching levels and innovative deals.”

That was unbelievably five years ago.

It was once famously said that, “Integration…is like M&Ms…a thin, sugary veneer of medical ‘science’ over a yummy core of price fixing…” (US Healthcare Executive).

In the US, health care providers are generally converge upon the view that competition concerns – namely the fear of violating competition law – have had a significant chilling effect on progress toward increased integration in the delivery of health care. This, it is claimed, has led to relative ‘conservatism’ over formal partnerships.

What happens in the UK depends on how ‘light touch’ Monitor ends to be – or whether it will be relatively supine. It is still claimed by some that the light touch regulation of the City, originally introduced by the Margaret Thatcher Conservative government, led to the City spiralling out of control.

Cartels are when companies act together to behave in a way together at the expense of the customer.

Quite irrespective of their clandestine character, cartels are difficult to prove due to their varying characteristics. Cartels can be evidentially complex in the sense that the duration and intensity of participation and the subsequent anti-competitive conduct on the market may vary and take different forms.

These specificities impose a near unbearable threshold for competition authorities to prove in detail an infringement, let aside to impose an appropriate sanction reflecting the cartelists’ real participation.

Montesquieu, in his seminal work ‘De l’esprit des lois’ observed that ‘natural equity demands that the degree of proof should be proportionable to the greatness of the accusation’. While the ‘greatness of the accusation’ in cartel infringements is undisputed – especially in light of the magnitude the incurred sanctions – it appears less clear to what extent this should affect the ‘degree of proof’ of those infringements, especially having regard to their specificities.

Article 101(1) TFEU sets out the European competition law position:

The following shall be prohibited as incompatible with the internal market all agreements between undertakings, decisions by associations of undertakings and concerted practices which may affect trade between Member States and which have as their object or effect the prevention, restriction or distortion of competition within the internal market, and in particular those which:
(a) directly or indirectly fix purchase or selling prices or any other trading conditions;
(b) limit or control production, markets, technical development, or investment;
(c) share markets or sources of supply;
(d) apply dissimilar conditions to equivalent transactions with other trading parties, thereby placing them at a competitive disadvantage;
(e) make the conclusion of contracts subject to acceptance by the other parties of supplementary obligations which, by their nature or according to commercial usage, have no connection with the subject of such contracts.

In a famous case called Bayer v Commission, the Court of the First Instance, for the first time ventured to define the term ‘agreement’ as a concept that ‘centres around the existence of a concurrence of wills between at least two parties, the form in which it is manifested being unimportant so long as it constitutes the faithful expression of the parties’ intention’.

Over two centuries ago, Adam Smith, the dean of free market economics, warned: “People of the same trade seldom meet together, even for merriment and diversion, but tbe conversa- tion ends in a conspiracy against the public, or in some contrivanee to raise prices.” ‘^

The costs of violating price-fixing laws are very high: lawyers’ fees, government fines, poor morale, damaged public image, civil suits, and now prison terms.

While the appearance of price collusion or price fixing may seem bad in the energy market, and unproven, what will happen behind ‘closed doors’ for procedures outsourced in the NHS is likely to be a hidden scandal.

There is some truth in making the energy market more ‘competitive’. One, often rarely discussed solution, way is to ‘differentiate the product’, such that they are not all selling the same thing.

For such a homogeneous item such as gas, it is difficult to propose to do this.

Differentiating hernia operations, the bread-and-butter of the cherrypicked NHS for ‘high volume, low cost procedures’, is easier. You can vary the quality of en-suite ‘refreshments’. It’s well known that cinemas attract clients not on the basis of the quality of films, but on their range of things to go with their popcorn.

It may be intrinsically more easy to distinguish different ‘integrated care packages’, by varying the relative proportions of physical healthcare, social care, and social care (the components of what Andy Burnham MP might call “whole person care”).

The “we’ve been doing it for years” phenomenon of collusive practices is a tougher nut to crack. But in some fairness, the new private health providers haven’t been “doing it for years”, as the jet engines for the Health and Social Care Act (2012) for competitive tendering – the section 75 regulations – have only just been legislated for.

Amazingly enough, some producers of ‘folding boxes’ were given hefty fines in the United States in the 1970s. The experience there was that executives in the convicted paper companies acknowledge that the lack of contact between them and company lawyers made it hard to apply the law.

Direct contact between operating managers and members of the legal staff seemed to be less frequent in the companies that were more heavily involved in the conspiracy.

As they say, we live in ‘interesting times’, but, helpfully on this occasion, the experience from other jurisdictions may be quite helpful. Don’t blame me – Le Grand and Propper started it!

“Co-epetition” – how collaborative competition might ultimately benefit the patient



Diogenes

The debate about competition is polar. Either you’re a believer or not.

Yet competition can co-exist with collaboration. Also, in theory, integration or bundling could even be seen as ‘anti-competitive behaviour’.

A trick will be ultimately to find a way in which integration of services cannot offend competition law. As an useful starting point, Curry and Ham (2010) suggest that there are three levels of integration, the top of which is a “a macro-level or systems-level integration”, in which a single organisation or network takes full clinical and fiscal responsibility for the spectrum of health services for a defined population, Underneath is a “meso-level integration of services” for patients with particular conditions, which encompasses a continuum of care for a subset of patients with those conditions.

Ultimately, clinical commissioning groups, whatever expertise they precisely consist of, will need to source services which promote highest quality and best choice for its patients. And yet the law has to reconcile one of its fundamental rules (that everyone is innocent unless otherwise proven guilty), and the law should not penalise people wishing to work together if it is for the benefit of the patient. One is reminded of Diogenes of Sinope (412-323 B.C.) who was seen roaming about Athens with a lantern in broad daylight and looking for an honest man but never finding one.

“Co-epetition” can mean a ‘joint dominance’ of suppliers of health services, provided their activity does not abuse that dominance or distort the market. There are good reasons in business management why certain parties might choose to coordinate their commercial conduct to benefit patients, such as in bundling. Despite certain conflicting interests, they also share strong common values and are exposed to common risks. Such synergies in competences is well known to be essential for building cohesive organisational entities, and in forcing strategic alliances even if there is formal relationship at all.

Unfortunately, joint or collective dominance has been traditionally treated by the Competition Authorities as equivalent to oligopolistic dominance. The concept of joint dominance has been developed under both Article 102 of the Treaty on the functioning of EU.  There is some consensus among National Health Service (NHS) researchers, managers and clinical leaders that increased integration within the health system will enable the NHS to respond better to the growing burden of chronic illnesses. In “real markets”, the prohibition laid down in Article 102 TFEU has been justified by the consideration that harm should not be caused to the consumer, either directly or indirectly by undermining the effective competition.  However, healthcare is not a “real market”. Unlike the other concepts, co-opetition (blend of cooperation and competition) focuses on both cooperation and competition at the same time.

Basic principles of co-opetitive structures have been described in game theory, a scientific field that received more attention with the book “Theory of Games and Economic Behavior” in 1944 and the works of John Forbes Nash on non-cooperative games. It is also applied in the fields of political science and economics and even universally [works of V. Frank Asaro, J.D.: Universal Co-opetition, 2011, and The Tortoise Shell Code, novel, 2012]. Although several people have been credited with inventing the term co-opetition, including Sam Albert, Microsoft’s John Lauer, and Ray Noorda, Novell’s founder, its principles and practices were fully articulated originally in the 1996 book, “Co-opetition”, by Harvard and Yale business professors, Adam M. Brandenburger and Barry J. Nalebuff.

One sincerely hopes that NHS management will be able to cope with the pace of this debate too. Competitors with such management ability will likely forge a co-opetitive relationship. When two companies compete fiercely in a market, they likely perceive each other as an enemy to defeat, and have less willingness to collaborate, even if they have complementary skills and resources. One day, the best minds in the world will probably ‘have a go’ at producing a coherent construct of this for the NHS quasimarket.

“Co-epetition” provides, furthermore, a mechanism for English health policy to revisit yet again the notion of “public private partnerships” which first probably became really sexy about a decad ago at the heart of the government’s attempts “to revive Britain’s public services”. A decade later, Cameron is still lingering with this particular revival. The problem with how this is sold is that many have rightly rubbished the idea that the private sector is necessarily more “efficient”, an ab initio basic assumption, The private sector, both accidentally and sometimes quite deliberately, introduces needless reduplication and waste, evidenced by the cost of wastage in the US health market. However, the “dream” is that, in trying to bring the public and private sector together, the government hopes that the management skills and financial acumen of the business community will create better value for money for taxpayers.

Globally, diabetes is the second biggest therapeutic “market segment”, behind oncology, in terms of revenues generated. IMS Institute of Healthcare Informatics forecasts that the global diabetic segment will grow to $48-53 billion by 2016. In India, it is already the fastest growing segment. Diabetes medicines currently fall into two broad categories — tablets and injectable insulin. While domestic players are market leaders in the conventional oral drugs segment (market share of 80 per cent), multinational corporations (17 percent) are fast catching up with patent-protected new generation oral drugs. The anti-diabetes market has been consistently growing well above the pharmaceutical market for the past few years. It is possible to see the future in this crowded market in a coupled business strategy that involves in-licensing one or more compounds (new products from multi-national corporations), while continuing with time tested, less expensive (own) products for the mass market.

If the NHS should wish work together with private providers in provision of integrated bundles of healthcare, and the feeling is mutual in a way which clearly promotes patient choice, assuming that all parties see a rôle for the private sector in the NHS, the legislative framework should be re-engineered immediately to reflect that. This should a pivotal task for Monitor to turn its attention to.

Whatever the precise approach taken to “co-epetition”, the current legislative guidance will need to much better defined to ensure that any form of integration does not offend the anti-competitive environment.

The author is extremely grateful for the rich conversations he has had with Dr Na’eem Ahmed who is the first person to the author’s knowledge to acknowledge the potential value of this mode of provider dynamics for the NHS.

Introducing collaboration into a competitive market: a perfect storm of NHS “bundling”?



bundlingAndy Burnham MP, Shadow Secretary of State for Health, announced at the Labour Party Annual Conference 2012, on 3 April 2012:

Andy Burnham 2012

 

 

However how to bring about a collaborative NHS is a formidable ask from a NHS which has just become geared up to private competition. To give an example, “bundles” in the NHS have been used, particularly by the Liberal Democrats and a beleaguered Earl Howe, to argue a case for ‘integrated care’ which has a whole plethora of meanings to healthcare experts. “Pure bundling” refers to a situation where products A and B can only be purchased together. This is the case, for example, when buying a business class ticket on the Eurostar, which includes a meal. Transport and meal can only be purchased together. “Mixed bundling” is where A and B can be purchased separately but purchasing them together is cheaper (there can be more than two products). This is what the Commission also refers to as “commercial tying”.

Allegations of anti-competitive bundling were significant parts of the antitrust cases against Microsoft in the United States and the European Union. Article 102 TFEU and s. 18 Competition Act provide a list of example behaviours that can constitute an abuse for these purposes and they are almost identical. The precise problem is making the conclusion of contracts subject to acceptance by the other parties of supplementary obligations which, by their nature or according to commercial usage, have no connection with the contracts. For example, on 24 March 2004 Microsoft decision (IP/04/382), the Commission found that the bundling of Windows Media Player as a compulsory product to take (for free) when customers bought Windows 98 or Windows XP was an abuse of a dominant position. The reasoning was based on the fact that suppliers of competing products to Windows Media Player were being pushed out of the market. In addition to a large fine, the Commission ordered Microsoft to make the operating systems available without Windows Media Player within 90 days.

“Bundling” is a key aspect of  “A fair playing field for the benefit of NHS patients” published by Monitor in February 2013.

FRONT COVER

 

 

 

 

 

 

 

 

 

According to Monitor,

“Commissioning a range of services from a single provider through “one block contract”  contract will sometimes be the best way to secure efficient, effective and coordinated care. In such cases, commissioners must be able to determine the appropriate price for the bundled set of services. In other circumstances, bundling may exclude smaller providers who are well placed to provide one element of the service bundle.

Getting bundling decisions right is critical to delivering integrated care to patients. Our evidence suggests that the current NHS pricing system may be a barrier to make the best bundling decisions, particularly in relation to community and mental health services. Improving the pricing system entails developing standardised currencies (descriptions of what is being purchased for a given price) and  better data on providers’ costs.”

In an excellent document called “The Health and Social Care Bill: Where next?” from the Nuffield Trust in May 2011, this tension between collaboration and competition had been revisited.

The authors wrote then,

“Ideally [they] should build on the Vertical Agreements Block Exemption provisions in EU competition law within Article 101 (which covers restrictive agreements) that applies to agreements entered into by two or more organisations operating at different levels along the production chain. Almost all such agreements are exempted provided that the market share of the parties is less than 30 per cent. The rules should also build on the experience of US regulators in proactively establishing examples of permitted models of competition and collaboration in so-called ‘safe harbours’, especially if the market share was greater than 30 per cent.”

This has led lawyers and philosophers to consider how we might be able to ‘collaborate in a competitive market’. David Boaz concludes that ‘collaboration is as much part of capitalism as competition.” As for the immediate problem of how bundling might be promoted in the implementation of the Health and Social Care Act, Earl Howe on 24 April 2013 seemed to appreciate that “unbundling” might lead to fragmentation, providing that,

“It is interesting that some stakeholders have raised concerns about unbundling leading to fragmentation, while others are concerned about the effects of bundling too many services together. In practice, it is for clinically led commissioners to take decisions on whether or not services should be bundled in the best interests of patients. That is their job, and these regulations do nothing to require them to bundle or unbundle, as I have said.”

But the guidance from Earl Howe and Monitor has not been that forthcoming about how integrated services through mechanisms such as bundling can be introduced so as to not offend EU competition law, given that the primary effect of the introduction of the Health and Social Care Act will be, as widely warned against, to introduce a fragmented privatised market into NHS services.

Click to listen highlighted text! Powered By GSpeech